Sandeep Bansal Joins bioAffinity Technologies’ Medical and Scientific Advisory Board

Sandeep Bansal, M.D., has become the newest member of bioAffinity Technologies Inc.’s Medical and Scientific Advisory Board. 
 
Bansal is the medical director for Lung Innovations Network, a patient-centered practice that offers comprehensive lung care to more than 10,000 patients in central and western Pennsylvania. The Network intends to incorporate bioAffinity Technologies’ CyPath Lung into its practice to help detect early-stage lung cancer. 
 
“As a clinician, I see hundreds of patients a year who can directly benefit from CyPath Lung. As a researcher, I am excited about the company’s ongoing studies to advance CyPath Lung, as well as noninvasive tests for other lung diseases,” Bansal said. “I look forward to contributing to bioAffinity’s approach to lung health by working with the company’s science team and the physicians and researchers who sit on its advisory board.”
 
Bansal has extensive experience in minimally invasive pulmonary procedures including navigational and robotic bronchoscopy, endobronchial ultrasound and chest sonography, argon plasma coagulation, cryotherapy, airway stenting, bronchoscopic lung volume reduction and indwelling pleural catheters. A principal investigator of multiple clinical research trials and a journal reviewer for several medical journals, he has been instrumental in developing a comprehensive lung center that allows a rapid assessment and management of healthcare needs based on the population characteristics and available resources. The model has successfully introduced advanced pulmonary services, including the latest technology and population health services, including a lung cancer screening program, to support the region’s clinical needs.
 
“Dr. Bansal is a highly regarded clinician and researcher who will be a strong addition to our stellar Medical and Scientific Advisory Board. His demonstrated commitment to saving lives and improving patients’ quality of life through innovative therapies and his prodigious research are truly impressive,” bioAffinity Technologies President/CEO Maria Zannes stated. “The caliber of our Advisory Board is a testament to the commitment each physician has placed on bringing breakthrough technology to market in the battle against lung cancer and other diseases of the lung.”
 
bioAffinity Technologies’ CyPath Lung uses advanced flow cytometry and artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. Automated data analysis helps determine if cancer is present or if the patient is cancer-free. CyPath Lung incorporates a fluorescent porphyrin, TCPP, that is preferentially taken up by cancer and cancer-related cells. Clinical study results demonstrated that CyPath Lung had 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters. 
 
San Antonio, Texas-based bioAffinity Technologies develops solutions for noninvasive diagnosis of early-stage cancer and lung diseases as well as broad-spectrum cancer treatment. Its CyPath Lung is marketed as a Laboratory Developed Test by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies.